FDA Approves Second LLS-Supported CAR T-cell Immunotherapy, A Revolutionary Approach to Cancer Treatment

Treatment approved for several types of B-cell lymphomas RYE BROOK, N.Y., Oct. 18, 2017 /PRNewswire-USNewswire/ — The Leukemia & Lymphoma Society (LLS) hails today’s U.S. Food and Drug Administration (FDA) approval of a new, personalized cell therapy that supercharges the patient’s immune system to find and kill cancer cells. The therapy, axicabtagene ciloleucel (Yescarta ™), is…